Logo

PharmaShots Weekly Snapshots (March 07-11, 2022)

Share this
PharmaShots Weekly Snapshots (March 07-11, 2022)

PharmaShots Weekly Snapshots (March 07-11, 2022)

AbbVie Entered into a Co-Development & License Agreement with Gedeon Richter to Develop & Commercialize Dopamine Receptor Modulators for Neuropsychiatric Diseases

Published: Mar 11, 2022 | Tags: AbbVie, Gedeon Richter, Dopamine Receptor Modulators, Neuropsychiatric Diseases

Passage Bio Reports the First Patient Dosing of PBKR03 in the P-I/II (GALax-C) Trial for the Treatment of Infantile Krabbe Disease

Published: Mar 11, 2022 | Tags: Passage Bio, P-I/II, GALax-C Trial, Infantile Krabbe Disease

Amarin Publishes Results of Vascepa (icosapent ethyl) in (REDUCE-IT) Study for the Treatment of Cardiovascular Diseases in JAHA 2022

Published: Mar 11, 2022 | Tags: Amarin, Vascepa, icosapent ethyl, REDUCE-IT Study, Cardiovascular Diseases, JAHA 2022

Erasca Entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate ERAS-007 and Erbitux (cetuximab) for Metastatic Colorectal Cancer

Published: Mar 11, 2022 | Tags: Erasca, Eli Lilly, ERAS-007, Cetuximab, Metastatic Colorectal Cancer

Samsung Bioepis and Biogen’s Byooviz (biosimilar, ranibizumab) Receive the Health Canada Approval for the Treatment of Retinal Vascular Disorders

Published: Mar 11, 2022 | Tags: Samsung Bioepis, Biogen, Byooviz, biosimilar, ranibizumab, Health Canada, Approval, Retinal Vascular Disorders

AbbVie Reports Results of Qulipta (atogepant) in P-III (PROGRESS) Trial for the Preventive Treatment of Chronic Migraine

Published: Mar 11, 2022 | Tags: AbbVie, Qulipta, atogepant, P-III, PROGRESS Trial, Chronic Migraine

Everest Licensing Partner Venatorx Report Results of Cefepime-Taniborbactam in P-III (CERTAIN-1) Study for Complicated Urinary Tract Infections

Published: Mar 10, 2022 | Tags: Everest, Venatorx, Cefepime-Taniborbactam, P-III, CERTAIN-1 Study, Complicated Urinary Tract Infections

Antengene’s ATG-101 Receives the NMPA’s IND Approval for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Published: Mar 10, 2022 | Tags: Antengene, ATG-101, NMPA, IND, Approval, Solid Tumors, Non-Hodgkin Lymphoma

Abivax Reports One-Year Maintenance Results of ABX464 in P-IIa Trial for the Treatment with Rheumatoid Arthritis

Published: Mar 10, 2022 | Tags: Abivax, ABX464, P-IIa, Trial, Rheumatoid Arthritis

Oncolytics Biotech Presents Results of Pelareorep + Bortezomib in P-Ib Study for the Treatment of Multiple Myeloma at the AACR 2022

Published: Mar 10, 2022 | Tags: Oncolytics Biotech, Pelareorep, Bortezomib, P-Ib, Study, Multiple Myeloma, AACR 2022

Denali Therapeutics Reports the Initiation of P-I/II Clinical Trial of DNL593 (PTV:PGRN) for the Treatment of Frontotemporal Dementia-Granulin

Published: Mar 10, 2022 | Tags: Denali Therapeutics, P-I/II, Clinical Trial, DNL593, PTV:PGRN, Frontotemporal Dementia-Granulin

Janssen Reports the Submission of a Type II Variation Application to the EMA for the Approval of a New Indication for Imbruvica (ibrutinib) for MCL

Published: Mar 10, 2022 | Tags: Janssen, Type II Variation Application, EMA, Imbruvica, ibrutinib, MCL

Pfizer Initiates P-II/III (EPIC-PEDS) Trial of Paxlovid (nirmatrelvir) for the treatment of Pediatric Patients with COVID-19

Published: Mar 09, 2022 | Tags: Pfizer, P-II/III, EPIC-PEDS Trial, Paxlovid, nirmatrelvir, COVID-19

Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A

Published: Mar 09, 2022 | Tags: Sobi, Sanofi, Efanesoctocog Alfa, BIVV001, P-III, XTEND-1 Study, Haemophilia A

Inventiva Reports the US FDA’s Acceptance of IND for Review of Lanifibranor and Empagliflozin for the Treatment of NASH and T2D

Published: Mar 09, 2022 | Tags: Inventiva, US, FDA, IND, Lanifibranor, Empagliflozin, NASH, T2D

Genmab’s Epcoritamab (DuoBody-CD3xCD20) Receives the US FDA’s Orphan-Drug Designation for the Treatment of Follicular Lymphoma

Published: Mar 09, 2022 | Tags: Genmab, Epcoritamab, DuoBody-CD3xCD20, US, FDA, Orphan-Drug Designation, Follicular Lymphoma

BridgeBio Entered into an Asset Purchase Agreement with Sentynl to Commercilize Nulibry (fosdenopterin) for Molybdenum Cofactor Deficiency

Published: Mar 09, 2022 | Tags: BridgeBio, Sentynl, Nulibry, fosdenopterin, Molybdenum Cofactor Deficiency

BioNTech Expands its 2020 Collaboration with Regeneron to Advance FixVac and Libtayo (cemiplimab) for the Treatment of NSCLC

Published: Mar 09, 2022 | Tags: BioNTech, 2020, Regeneron, FixVac, Libtayo, cemiplimab, NSCLC

Valneva Reports Completion of VLA1553 in P-III (VLA1553-301) Trial for the Treatment of Chikungunya

Published: Mar 08, 2022 | Tags: Valneva, VLA1553, P-III, VLA1553-301 Trial, Chikungunya

Voyager Therapeutics Entered into a License Option Agreement with Novartis to Develop Gene Therapies for the Treatment of Neurological Diseases

Published: Mar 08, 2022 | Tags: Voyager Therapeutics, Novartis, Gene Therapies, Neurological Diseases

Alpine Immune Sciences Reports the US FDA's Clinical Hold on (NEON-2) Trial of Davoceticept (ALPN-202) for Advanced Malignancies

Published: Mar 08, 2022 | Tags: Alpine Immune Sciences, US, FDA, Clinical Hold, NEON-2 Trial, Davoceticept, ALPN-202, Pembrolizumab, Advanced Malignancies

Targovax ASA Entered into a Clinical Collaboration and Supply Agreement with Agenus TG Mutant KRAS Cancer Adjuvanted with QS-21 STIMULON

Published: Mar 08, 2022 | Tags: Targovax ASA, Agenus, TG Mutant, KRAS Cancer, QS-21 STIMULON

Astellas Reports Results of Fezolinetant in P-III (SKYLIGHT 4) Trial for the Treatment of Vasomotor Symptoms Associated with Menopause

Published: Mar 08, 2022 | Tags: Astellas, Fezolinetant, P-III, SKYLIGHT 4 Trial, Vasomotor Symptoms, Menopause

Merck Reports Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-716) Trial for the Treatment of Resected Stage IIB and IIC Melanoma

Published: Mar 08, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-716 Trial, Stage IIB, IIC Melanoma

Spectrum Presents Results of Poziotinib in (ZENITH20) Clinical Trial as 1L Treatment of NSCLC at ESMO TAT 2022

Published: Mar 07, 2022 | Tags: Spectrum, Poziotinib, ZENITH20 Clinical Trial, NSCLC, ESMO TAT, 2022

Kintor Pharma Reports the Completion of Patient Enrollment in P-II Clinical Trial of KX-826 for Female Patients with Androgenetic Alopecia

Published: Mar 07, 2022 | Tags: Kintor Pharma, P-II, Clinical Trial, KX-826, Androgenetic Alopecia

Equillium Reports Initiation of P-III (EQUATOR) Study for Itolizumab as 1L Treatment of Acute Graft-Versus-Host Disease

Published: Mar 07, 2022 | Tags: Equillium, P-III, EQUATOR Study, Itolizumab, Acute Graft-Versus-Host Disease

BMS’s Opdivo (nivolumab) Receives the US FDA’s Approval as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

Published: Mar 07, 2022 | Tags: BMS, Opdivo, nivolumab, US, FDA, Approval, Non-Small Cell Lung Cancer

Junshi Biosciences and Coherus Publishes Results of Toripalimab in P-III (JUPITER-06) Study for Esophageal Squamous Cell Carcinoma in Cancer Cell

Published: Mar 07, 2022 | Tags: Junshi Biosciences, Coherus, Toripalimab, P-III, JUPITER-06 Study, Esophageal Squamous Cell Carcinoma, Cancer Cell

Altamira Entered into an Exclusive License and Distribution Agreement with Nuance Pharma to Develop and Commercialize Bentrio Nasal Spray

Published: Mar 07, 2022 | Tags: Altamira, Nuance Pharma, Bentrio Nasal Spray


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions